Deltex Medical wins EU grant for blood monitoring product

The AIM-listed company was awarded the grant from the EU’s Horizon 2020 programme which finances feasibility studies for bringing new products on to the market, and it could be followed by up to €2.5m under phase two of Deltex’s medical product development.

Deltex, along with Lariboisiere Hospital in Paris, have developed a system which provides simultaneous visual display of a patient's aortic blood flow velocity and aortic blood pressure called called TruVue, which is expected to significantly contribute to patient safety.

The EU funding will help Deltex test the system with users and collect feedback about their experience with the graphical user interface and help work out the price of a multinational clinical trial for phase two.

The €50,000 grant is to be received in the first half of the year and the company will be able to apply for phase two funding as soon as it is able to demonstrate success from the feasibility work.

Deltex chief executive Ewan Phillips said: "We are delighted to receive this endorsement and the potential for the larger phase two award, although there can be no certainty as to if, or when this may come to fruition.

"The phase one grant coincides with our plan to release the Velocity Pressure loop software, developed in partnership with Labroisiere Hospital in Paris, to select clinical experts in the second half of the year for clinical trials.”

The software is predicated on the CardioQ-ODM+'s ability to measure continuously central blood flows and arterial blood pressure, which can provide new insight into changes in patients' vascular resistance and compliance.

Shares in Deltex Medical up 4.12% to 4.16p at 0830 BST.